Free Daily Podcast Summary
The Readout Loud: Daily Summaries Delivered
by STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 4 days ago28 min
Definium's new psychedelics data, and a reprieve for international scientists
International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this week's episode of "The Readout LOUD." STAT reporter Jonathan Wosen and Fanta Aw, the executive director of NAFSA: Association of International Educators, join the podcast to discuss a recent court decision around foreign visas for students. We also discuss the Definium's psychedelics data and what it means for that field as a whole. Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.
- 1 weeks ago30 min
Why two promising heart drugs flopped and what's next
On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean for the development of new heart medicines moving forward? Cardiologist and biotech entrepreneur Ethan Weiss joins us to discuss the surprising failures and long-term implications of two large clinical trials involving drugs developed from Novo Nordisk and Novartis, respectively. Plus, we have a recap of biotech news we missed while on hiatus, including a spurt of FDA drug approvals and the next big thing in cancer treatment from Merck and Moderna.
- Jul 30, 202636 min
411: Capricor's data clash and a fugitive in the C-suite
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.It's a big week for FDA advisory committee meetings. Allison, Elaine, and Adam discuss Capricor Therapeutics' hearing in front of an FDA advisory committee. The company is asking the agency to approve its treatment for Duchenne, but advisers have questioned the data the company presented. They also discuss Replimmune's meeting with advisers to discuss its immunotherapy for melanoma.The hosts further discuss the latest news in the life sciences, including new details on how a fugitive worked as a biotech executive, cuts at GSK, and Sarepta Therapeutics' new CEO.
- Jul 23, 20261h 4m
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We speak with our colleagues Jason Mast and Matthew Herper about their impactful look at one father’s mission to develop a treatment for his daughter’s ultra-rare disease. The subject of that feature, Matt Wilsey, also joins us.
- Jul 16, 202635 min
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. Soon, you’ll be able to make bets on the outcomes of clinical trials and FDA drug reviews. Is that a good thing? We’ll discuss the issues with Jonathan Kimmelman, a bioethicist at McGill University who has researched prediction in clinical trials. We also chat about Biogen and its tau-lowering drug for Alzheimer’s. A mid-stage clinical trial presented this week showed the drug reduced levels of the tau protein and slowed the rate of cognitive decline in patients. But the data also raised a lot of questions that left experts and investors debating the drug’s future.
- Jul 9, 202643 min
408: Whistleblower takes on health insurance and FDA commissioner candidates
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. STAT reporter Bob Herman joins us to discuss his new series, "Out of Pocket, Out of Reach," which dives into how soaring costs for health insurance are hurting Americans and small business owners. We also speak with Chris Deacon, who filed a whistleblower lawsuit after spotting how an insurer may have violated contracts to provide health benefits for New Jersey's state workers. We also discuss the latest news in life sciences, including Anthropic's push into drug development and Vertex's largest-ever acquisition.
- Jun 25, 202642 min
407: The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program. We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.
- Jun 18, 202636 min
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a closely watched gene therapy for Huntington’s disease, clearing a path for its maker, the biotech company UniQure, to file for U.S. approval. Joining us to discuss this new development and what it means for the Huntington’s community is Lauren Holder, a Huntington’s disease advocate who is living with the early stages of the disease. A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job as the secretary of the Department of Health and Human Services. He entered the role with a long to-do list, and a goal of delivering measurable improvements within two years. How has he fared? Isabella Cueto, STAT’s chronic disease reporter, has been closely tracking Kennedy and the MAHA movement’s actions, and joins us to discuss.
Get The Readout Loud summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Drug Story
Each episode explores the unexpected stories behind prescription drugs and the business of treating illness.
Science Magazine Podcast
Weekly episodes covering original scientific research, global science news, and expert commentary.
Plenary Session
A medical oncologist discusses cancer care, health policy, and evidence-based medicine.
Stock Movers
Daily analysis of top-performing and struggling stocks across global markets, covering major sectors and breaking investment news.
The Best One Yet
Daily business news explained through sharp analysis and witty commentary, delivered in concise 20-minute episodes.
Wellness, Actually with Emily Oster & Perry Wilson, MD
Two experts analyze health news, debunk wellness myths, and answer listener questions using data and medical evidence.
Unbiased Science
Two scientists analyze health topics using objective, evidence-based approaches to inform everyday decisions.
After the Fact
Explores data and trends shaping public health, environment, and economic issues through expert analysis and nonpartisan discussion.
The Weirdest Thing I Learned This Week
Three science journalists share bizarre and little-known facts they’ve recently discovered.
The Pulse
Explores surprising stories in health and science, from operating rooms and labs to breakthrough innovations.
This Week in Cardiology
A weekly summary and analysis of key developments in cardiology for healthcare professionals.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
About The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Readout Loud in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Readout Loud daily summary?
It's a free AI-powered email that summarizes new episodes of The Readout Loud as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Readout Loud podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Readout Loud product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by STAT.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Readout Loud release new episodes?
The Readout Loud publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Readout Loud cover?
The Readout Loud covers topics including Business. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Readout Loud summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.